Empagliflozin (Jardiance) for Heart Failure
Date: November 16, 2020
Issue #:
1611Summary:
In a randomized, placebo-controlled trial, the
sodium-glucose cotransporter 2 (SGLT2) inhibitor
empagliflozin (Jardiance– Boehringer Ingelheim/Lilly)
reduced the composite risk of cardiovascular death
or hospitalization for worsening heart failure (HF)
in patients with heart failure with reduced ejection
fraction (HFrEF), whether or not they had type 2
diabetes. To date, empagliflozin has not been
approved by the F DA for such use. The SGLT2 inhibitor
dapagliflozin(Farxiga) was approved by the FDA for
this indication earlier this year.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: admin Source Type: research
More News: Cardiology | Cardiovascular | Dapagliflozin | Diabetes | Diabetes Type 2 | Drugs & Pharmacology | Empagliflozin | Endocrinology | Forxiga | Heart | Heart Failure | Jardiance | SGLT2 Inhibitors | Sodium